Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Polymorphisms in β₂-adrenergic receptors, particularly at amino acid positions 16 and 164, significantly influence bronchodilator effectiveness and heart failure outcomes. Patients homozygous for Arg16 show heightened responses to β₂-agonists like albuterol, while the 164Ile variant correlates with reduced receptor function and adverse cardiovascular effects. These genetic variations explain why individuals respond differently to the same drug dose.

Apolipoprotein E polymorphisms, especially the apoE4 allele, influence both lipid metabolism and neurological drug responses. ApoE4 carriers show reduced efficacy of lipid-lowering therapies and diminished cognitive improvement with Alzheimer's disease medications like acetylcholinesterase inhibitors compared to non-carriers. This genotype-based variation has led clinicians to stratify therapeutic approaches based on apoE status.

Thymidylate synthase polymorphisms involving variable tandem repeats in its 5'-untranslated region affect TS expression levels and chemotherapy efficacy. The 3R/3R genotype produces higher TS mRNA and protein, reducing 5-fluorouracil effectiveness by enhancing DNA synthesis capacity. Colorectal and leukemia patients with the 3R/3R genotype show poorer treatment outcomes, making TS genotyping valuable for guiding chemotherapy decisions.

Genetic polymorphisms in drug target genes alter receptor function, enzyme activity, or protein expression, leading to variable drug binding and therapeutic effects across individuals. These variations affect both drug efficacy and toxicity independent of drug metabolism. Understanding these pharmacogenetic phenotypes alterations in pharmacokinetics drug targets enables clinicians to predict individual responses and optimize personalized therapies.

Drug target polymorphisms alter the structure or expression of receptors, enzymes, or proteins that drugs bind to, directly affecting drug response at the site of action. Drug metabolism polymorphisms influence how the body processes and eliminates drugs. While early pharmacogenetics focused on metabolism, current research increasingly examines drug target genes to predict both therapeutic efficacy and adverse effects.

Pharmacogenomic profiling identifies genetic variations in drug targets, enabling clinicians to predict individual drug responses and tailor therapies accordingly. By matching patients to drugs based on their genotype, clinicians can enhance therapeutic precision, minimize adverse effects, and optimize dosing strategies. This approach transforms treatment from a one-size-fits-all model to individualized, genotype-guided therapy.

The most clinically relevant polymorphisms include β₂-adrenergic receptor variants affecting cardiovascular and pulmonary drug responses, apoE4 influencing lipid-lowering and Alzheimer's disease therapies, and thymidylate synthase variants guiding chemotherapy selection. These polymorphisms have strong evidence linking genotype to treatment outcomes, making them valuable biomarkers for stratifying patients and predicting therapeutic success or failure.